Joint Pain News and Research

RSS

People with CFS to benefit from Griffith’s National Centre for Neuroimmunology and Emerging Diseases

People living with chronic fatigue are set to benefit with the opening next week (Dec 2), of the National Centre for Neuroimmunology and Emerging Diseases at Griffith University.

30 Nov 2013

Results announced for Phase 3B/4 study of RAPAMUNE in kidney transplant patients

Pfizer Inc. (NYSE:PFE) announced today top-line results from a Phase 3B/4 study of RAPAMUNE® (sirolimus) evaluating kidney transplant patients who transitioned from tacrolimus-based therapy (TAC) to RAPAMUNE® 3 to 5 months after transplant.

12 Nov 2013

Viewpoints: The battle over one woman's medical story; why Mass. didn't see a wave of cancellations; politicians' love of anecdotes

Edie Littlefield Sundby may not have thought she'd ignite a national debate when the stage-4 cancer survivor asked us to publish her Monday op-ed on losing her oncologist due to the Affordable Care Act. But she certainly has, and it's important to understand why. Mrs. Sundby and millions like her must be denied their medical choices if ObamaCare is going to work as its liberal planners intend (11/6).

8 Nov 2013

Most severely obese teenagers who underwent bariatric WLS experience no major complications

Most severely obese teenagers who underwent bariatric weight-loss surgery (WLS) experienced no major complications, according to a study published by JAMA Pediatrics, a JAMA Network publication.

5 Nov 2013

Experimental drug effective in treating patients with non-small cell lung cancer

An experimental cancer drug that has shown promise in the treatment of melanoma has also shown early potential as an effective treatment for patients with non-small cell lung cancer, the leading cause of cancer death among men and women worldwide.

4 Nov 2013

Promising melanoma drug demonstrates potential for non-small cell lung cancer treatment

An experimental new cancer drug called MK-3475, which has shown dramatic promise for treating melanoma is also showing early potential as an effective treatment for patients with non-small cell lung cancer, the leading cause of cancer death of men and women worldwide.

30 Oct 2013

Phase 3 study shows STELARA inhibits structural damage in patients with active psoriatic arthritis

New findings from two integrated Phase 3 Janssen Research & Development, LLC (Janssen)-sponsored studies showed treatment with STELARA- (ustekinumab) resulted in significantly greater inhibition of structural damage in patients with active psoriatic arthritis compared with placebo.

29 Oct 2013

Patients with psoriatic arthritis benefit from early aggressive drug treatment, says study

People with a type of arthritis affecting the skin and joints respond significantly better to early, aggressive drug treatment compared to standard care, according to preliminary results presented by a University of Leeds lecturer to a major US conference.

29 Oct 2013

Delaying rheumatoid arthritis treatment could greatly increase likelihood of joint damage

Delaying treatment for rheumatoid arthritis could greatly increase the likelihood that patients will suffer joint damage and experience disability two years out, according to a new study from Vivian Bykerk, M.D. at Hospital for Special Surgery. The research will be presented at the annual meeting of the American College of Rheumatology/Association of Rheumatology Health Professionals on October 28 in San Diego.

28 Oct 2013

Self-directed walking program shows promise in easing joint stiffness in older breast cancer patients

A self-directed walking program shows promise in easing joint stiffness in older women who experienced these symptoms while taking aromatase inhibitor therapy for breast cancer, according to research presented this week at the American College of Rheumatology Annual Meeting in San Diego.

28 Oct 2013

Patellofemoral knee brace can improve pain, bone marrow lesions in knee osteoarthritis patients

Use of a patellofemoral knee brace can improve pain symptoms and bone marrow lesions in patients with a type of osteoarthritis of the knee, according to new research findings presented this week at the American College of Rheumatology Annual Meeting in San Diego.

28 Oct 2013

European Commission approves updated label of Prevenar 13 for high risk pneumococcal disease

Pfizer Inc. (NYSE:PFE) announced today that the European Commission approved updates to the Summary of Product Characteristics (SmPC) for the company's pneumococcal conjugate vaccine Prevenar 13* (pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed]), regarding its use in certain populations at high risk of pneumococcal disease.

18 Oct 2013

FDA accepts, files Genentech's sBLA for subcutaneous use of Xolair in people with CIU

Genentech, a member of the Roche Group, today announced that the U.S. Food and Drug Administration has accepted and filed the company's supplemental Biologics License Application for subcutaneous use of Xolair (omalizumab) in people with Chronic Idiopathic Urticaria who remained symptomatic despite treatment with H1-antihistamine therapy at approved doses.

11 Oct 2013

Osteoarthritis and exercise: an interview with Dr Nicola Walsh, Associate Professor at the University of the West of England

Exercise helps to keep the surrounding muscles strong to protect the joint, and also reduces stiffness that people frequently experience in the morning or after periods of inactivity. Joints are meant to move, so keeping them mobile will assist with joint health, maintain range of movement and enhance stability.

7 Oct 2013

Newly discovered compound could be developed as antifungal drug to treat fungal infections

On a molecular level, you have more in common with shower curtain mold or the mushrooms on your pizza than you might think. Humans and fungi share similar proteins, a biological bond that makes curing fungal infections difficult and expensive.

7 Oct 2013

FDA approves STELARA (Ustekinumab) for treatment of active psoriatic arthritis

Janssen Biotech, Inc., announced today that the U.S. Food and Drug Administration (FDA) has approved STELARA® (ustekinumab) alone or in combination with methotrexate for the treatment of adult patients (18 years or older) with active psoriatic arthritis.

23 Sep 2013

Gout: An Interview with Dr. Lawrence Edwards, Chairman and CEO of GUAES

Gout is the most common form of inflammatory arthritis that affects adults. It's a disease caused by the presence of uric acid crystals in and around the joints. It's a disease that's becoming more and more common. It probably has doubled in its prevalence worldwide over the past twenty to thirty years.

18 Sep 2013

Calcium and vitamin D supplements have no effect on joint symptoms in postmenopausal women

A team of investigators systematically analyzed the effect of calcium and vitamin D supplementation on joint symptoms in a rigorous and controlled study of postmenopausal women. They found that supplementation did not reduce the severity of joint symptoms reported by the participants.

17 Aug 2013

Scientists uncover potential drug target for effective therapy against bacterial disease brucellosis

UC Davis scientists have uncovered a potential drug target for the development of an effective therapy against the debilitating, chronic form of the bacterial disease brucellosis, which primarily afflicts people in Mediterranean and Middle Eastern countries.

16 Aug 2013

Joint symptoms in postmenopausal women not reduced by calcium and vitamin D supplements

A team of investigators systematically analyzed the effect of calcium and vitamin D supplementation on joint symptoms in a rigorous and controlled study of postmenopausal women.

16 Aug 2013

Joint Pain News and Research

People with CFS to benefit from Griffith’s National Centre for Neuroimmunology and Emerging Diseases

Results announced for Phase 3B/4 study of RAPAMUNE in kidney transplant patients

Viewpoints: The battle over one woman's medical story; why Mass. didn't see a wave of cancellations; politicians' love of anecdotes

Most severely obese teenagers who underwent bariatric WLS experience no major complications

Experimental drug effective in treating patients with non-small cell lung cancer

Promising melanoma drug demonstrates potential for non-small cell lung cancer treatment

Phase 3 study shows STELARA inhibits structural damage in patients with active psoriatic arthritis

Patients with psoriatic arthritis benefit from early aggressive drug treatment, says study

Delaying rheumatoid arthritis treatment could greatly increase likelihood of joint damage

Self-directed walking program shows promise in easing joint stiffness in older breast cancer patients

Patellofemoral knee brace can improve pain, bone marrow lesions in knee osteoarthritis patients

European Commission approves updated label of Prevenar 13 for high risk pneumococcal disease

FDA accepts, files Genentech's sBLA for subcutaneous use of Xolair in people with CIU

Osteoarthritis and exercise: an interview with Dr Nicola Walsh, Associate Professor at the University of the West of England

Newly discovered compound could be developed as antifungal drug to treat fungal infections

FDA approves STELARA (Ustekinumab) for treatment of active psoriatic arthritis

Gout: An Interview with Dr. Lawrence Edwards, Chairman and CEO of GUAES

Calcium and vitamin D supplements have no effect on joint symptoms in postmenopausal women

Scientists uncover potential drug target for effective therapy against bacterial disease brucellosis

Joint symptoms in postmenopausal women not reduced by calcium and vitamin D supplements

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News